Compare · BASI vs INCY
BASI vs INCY
Side-by-side comparison of Bioanalytical Systems, Inc. (BASI) and Incyte Corp. (INCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BASI and INCY operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY carries a market cap of $24.01B.
- INCY has hit the wire 24 times in the past 4 weeks while BASI has been quiet.
- INCY has more recent analyst coverage (25 ratings vs 0 for BASI).
- Company
- Bioanalytical Systems, Inc.
- Incyte Corp.
- Price
- -
- $118.43-0.87%
- Market cap
- -
- $24.01B
- 1M return
- -
- +1.34%
- 1Y return
- -
- +51.74%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- News (4w)
- 0
- 24
- Recent ratings
- 0
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest BASI
- SEC Form RW filed by Bioanalytical Systems, Inc.
- SEC Form 8-K filed by Bioanalytical Systems, Inc.
- Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.
- Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
- Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN
- SEC Form 8-K filed
- Colliers Securities resumed coverage on Bioanalytical Systems with a new price target
- SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units
- Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference
- SEC Form EFFECT filed
Latest INCY
- New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
- Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
- SEC Form 10-Q filed by Incyte Corp.
- Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 4 filed by EVP, Head of Tech. Operations Morrissey Michael James
- SEC Form 4 filed by EVP, Head of Incyte Intl Heeson Lee
- Principal Accounting Officer Tray Thomas was granted 2,834 shares, increasing direct ownership by 15% to 21,699 units (SEC Form 4)
- CMO & Head of Late-Stage Dev. Stein Steven H sold $215,348 worth of shares (1,877 units at $114.73) and was granted 9,798 shares, increasing direct ownership by 34% to 30,916 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A was granted 5,916 shares, increasing direct ownership by 10% to 63,628 units (SEC Form 4)